Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta‐analysis‐based comparison of treatment efficacy

医学 荟萃分析 置信区间 掌跖脓疱病 随机对照试验 优势比 梅德林 分级(工程) 系统回顾 随机效应模型 内科学 物理疗法 皮肤病科 银屑病 工程类 土木工程 政治学 法学
作者
Takemichi Fukasawa,Takashi Yamashita,Atsushi Enomoto,Asako Yoshizaki‐Ogawa,Kiyoshi Miyagawa,Shinichi Sato,Ayumi Yoshizaki
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:38 (2): 281-288 被引量:5
标识
DOI:10.1111/jdv.19499
摘要

Few studies have made direct comparisons between treatments for palmoplantar pustulosis (PPP); therefore, it is difficult to select the best treatment for each patient. To determine the best therapy and to compare reported measures of efficacy in clinical trials of systemic treatments for PPP in this systematic review and network meta-analysis. Six databases were used to perform database search on 10 July 2022. Randomized controlled trials (RCTs) were identified through a systematic literature search. The titles and abstracts of articles were initially screened for inclusion by two authors independently using our predetermined criteria. The full texts of selected articles were then independently assessed for inclusion in a blinded fashion. Disagreement between the authors was resolved by consensus. Data were abstracted in duplicate. Random-effects model was accepted to perform network meta-analysis. Assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed according to the PRISMA guidelines. The analysis was completed in July 2022. The primary outcome was the change of PPP Area and Severity Index (PPPASI) from baseline and the secondary outcome was the achievement of PPPASI-50 response. Seven RCTs with 567 patients were included. Guselkumab 100 mg was the one with the highest probability of reaching the proposed outcomes (mean difference [MD], -8.00; 95% confidence interval [CI], 4.88-11.11), while the achievement of PPPASI-50 response did not show a significant difference (odds ratio [OR], 3.79; 95% CI, 0.51-28.37). Guselkumab 200 mg was next to 100 mg of reaching the proposed outcomes (MD, -4.71; 95% CI, 2.12-7.30), while the achievement of PPPASI-50 response did not show a significant difference (OR, 2.34; 95% CI, 0.48-11.43). Network meta-analysis showed guselkumab 100 mg was the treatment with the highest probability of reaching both PPPASI and PPPASI-50 outcomes. Absolute PPPASI may be more appropriate as an outcome than PPPASI-50.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
浮游应助Pierce采纳,获得10
1秒前
bbhk完成签到,获得积分10
2秒前
wwqc完成签到,获得积分0
2秒前
Ting发布了新的文献求助20
3秒前
耳火发布了新的文献求助10
3秒前
月月完成签到,获得积分10
3秒前
chen关注了科研通微信公众号
3秒前
4秒前
琳666发布了新的文献求助30
4秒前
4秒前
朱祥龙发布了新的文献求助30
5秒前
6秒前
6秒前
7秒前
wml应助Li采纳,获得10
7秒前
夏晴晴完成签到,获得积分10
8秒前
8秒前
9秒前
受伤尔曼完成签到,获得积分10
9秒前
Pierce完成签到,获得积分10
9秒前
Yu发布了新的文献求助10
10秒前
耳火完成签到,获得积分10
10秒前
zhaosibo020118完成签到,获得积分10
10秒前
CC完成签到,获得积分10
10秒前
11秒前
11秒前
Lucas应助科研通管家采纳,获得30
11秒前
浮游应助科研通管家采纳,获得10
11秒前
隐形曼青应助科研通管家采纳,获得10
11秒前
Owen应助科研通管家采纳,获得10
11秒前
求助人员应助科研通管家采纳,获得10
11秒前
文静香薇完成签到 ,获得积分20
11秒前
3333r应助科研通管家采纳,获得10
11秒前
11秒前
AAA应助科研通管家采纳,获得10
11秒前
spc68应助科研通管家采纳,获得10
11秒前
田様应助科研通管家采纳,获得10
11秒前
华仔应助科研通管家采纳,获得10
11秒前
彭于晏应助科研通管家采纳,获得10
12秒前
云溪应助科研通管家采纳,获得20
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Binary Alloy Phase Diagrams, 2nd Edition 6000
Encyclopedia of Reproduction Third Edition 3000
Comprehensive Methanol Science Production, Applications, and Emerging Technologies 2000
化妆品原料学 1000
The Political Psychology of Citizens in Rising China 800
1st Edition Sports Rehabilitation and Training Multidisciplinary Perspectives By Richard Moss, Adam Gledhill 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5637553
求助须知:如何正确求助?哪些是违规求助? 4743563
关于积分的说明 14999628
捐赠科研通 4795653
什么是DOI,文献DOI怎么找? 2562146
邀请新用户注册赠送积分活动 1521595
关于科研通互助平台的介绍 1481573